Key result
Convalescent serum therapy is ineffective in preparalytic poliomyelitis because antibodies cannot reach the virus in the central nervous system.
Why the study?
Does convalescent serum improve outcomes in preparalytic poliomyelitis?
Does convalescent serum improve outcomes in preparalytic poliomyelitis?
Convalescent serum therapy is likely ineffective for poliomyelitis due to the virus's neurotropic nature preventing antibody access.
Does not support serum use in preparalytic polio; leaves open CNS antibody delivery strategies for neurotropic viruses.
Summary and Conclusions The pathogenesis of poliomyelitis, as a disease transmitted by nerve fibers and entirely neurotropic, suggests the ineffectiveness of serum therapy. Additional experimental data concerning the use of large quantities of serum, or whole blood, in the various stages of the disease, give further evidence to its lack of value. Therefore, in serum therapy one is faced with two possibilities: Antibody can never reach the virus in the central nervous system. Still larger amounts must be used, e.g., hyperimmune horse serum, but from the data herewith given the likelihood of success with such a serum is slight.
No takes yet. Share an insight, caveat, or question.
Maurice Brodie (1935) conducted a review in Preparalytic Poliomyelitis. Convalescent serum therapy was evaluated. Convalescent serum therapy is ineffective in preparalytic poliomyelitis because antibodies cannot reach the virus in the central nervous system.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: